Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Ornstein on Role of IL-2 in Patients With RCC

July 24th 2017

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).

Expert Discusses Biomarker Development in GU Cancers

July 24th 2017

William Oh, MD, reviews some of the biomarkers under investigation in GU cancers and possibilities for major advances in the field over the next few years.

Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma

July 22nd 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has taken a positive position on indications for atezolizumab in non-small cell lung cancer and urothelial carcinoma.

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

July 21st 2017

Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer

July 21st 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.

Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

July 21st 2017

Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

July 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma

July 19th 2017

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma.

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

July 19th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

Unmet Needs in Kidney Cancer

July 17th 2017

Kidney Cancer: Non-Clear Cell Histology

July 17th 2017

Kidney Cancer: Vaccine-Based Approaches

July 17th 2017

Novel Combinations in Kidney Cancer

July 17th 2017

Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

New Strategies in Kidney Cancer

July 17th 2017

Immunotherapy in Kidney Cancer

July 17th 2017

Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

Frontline TKI Strategies in Kidney Cancer

July 17th 2017